Evaluating the effect of myrtenal on urinary bladder damage induced by a nitrosamine derivative in gamma- irradiated rats

Abstract

Bladder cancer is one of the most common urinary system malignancies worldwide occurring in both sexes. It is more frequent in men than women, and the incidence and mortality rate of bladder cancer greatly increased in the recent years. Cigarette smoking is the main risk factor for the development of urothelial tumor. Other risk factors may include exposure to arsenic in drinking water, occupational exposure to aromatic amines, and genetic alterations. A large number of chemotherapeutic agents including natural and synthetic compounds have been identified as having some potential cancer therapeutic value such as inhibiting mutagenesis, hyperproliferation or induce apoptosis or differentiation. Current scientific interest in the management of cancer is directed towards the utilization of naturally occurring compounds for chemotherapeutics. The current investigation was designed to evaluate the therapeutic activity of myrtenal in N-butyl-N-(4- hydroxybutyl)-nitrosamine (BBN)-induced bladder carcinoma model with the objective of elucidating the modulatory role in the inflammatory and apoptotic proteins and anti-oxidant property in animal models as well as the antioxidant potential in the applied animal model.